EUVIMEDEUVIMED entdecken
Crossref

Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells

Guo-Qiang Zhang, Chuang Xi, Chen-Tian Shen, Hong-Jun Song, Quan-Yong Luo iD, Zhong-Ling Qiu

Endocrine-Related Cancer · 01.06.2023 · 30 (9)

DOI: 10.1530/erc-23-0130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, erschienen am 01.06.2023. Verfasst von Guo-Qiang Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Symporters. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radioiodine treatment is a fundamental therapy for patients with papillary thyroid cancer (PTC). Sodium/iodide symporter (NIS)-mediated iodine uptake is a prerequisite for the efficacy of radioiodine therapy. Interleukin-6 (IL-6) is a pro-tumor cytokine, but its regulation of NIS expression in PTC has not been elucidated. In this study, we found that IL-6 enhanced the proliferation ability of PTC cells. Moreover, the negative association between IL-6 and NIS expression in thyroid cancer tissues was demonstrated. IL-6 downregulated thyroid-specific genes such as NIS, thyroid peroxidase, and thyroid-stimulating hormone receptor and thyroid-specific transcription factors including thyroid transcription factor-1 (TTF-1) and paired box protein-8 (PAX-8). The inhibitory effects of IL-6 on NIS expression were alleviated by mitogen-activated protein kinase and Janus kinase inhibitors. Depletion of c-Jun or STAT3 also rescued IL-6-induced NIS downregulation, with STAT3 depletion exerting a stronger effect. TTF-1 protein expression was also restored by depleting c-Jun or STAT3. STAT3 depletion, but not c-Jun depletion, alleviated the inhibitory effect of IL-6 on PAX-8 expression. Moreover, the downregulation of NIS by IL-6 was rescued by overexpressing TTF-1 and PAX-8. Tocilizumab, an IL-6 receptor blocker, did not have any cytostatic activity in PTC cells, and it also failed to induce redifferentiation in vitro . However, we found that the drug blocked the inhibitory effect of IL-6 on NIS expression. In summary, IL-6 inhibits NIS transcription in PTC cells by activating mitogen-activated protein kinase and Janus kinase signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsSymportersHumansThyroid Cancer, PapillaryInterleukin-6Iodine RadioisotopesMitogen-Activated Protein Kinases

Stichwörter der Autor:innen

dedifferentiationinterleukin-6papillary thyroid cancersodium/iodide symporter

Substanzen

Interleukin-6Iodine RadioisotopesMitogen-Activated Protein KinasesSymporters

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Quan-Yong Luo

Zitieren

APA

Zhang, G. Q., Xi, C., Shen, C. T., Song, H. J., Luo, Q. Y., & Qiu, Z. L. (2023). Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells. Endocrine-Related Cancer, 30(9). https://doi.org/10.1530/erc-23-0130

Vancouver

Zhang GQ, Xi C, Shen CT, Song HJ, Luo QY, Qiu ZL. Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells. Endocrine-Related Cancer. 2023;30(9). doi:10.1530/erc-23-0130

BibTeX
@article{Zhang2023,
  author = {Zhang, Guo-Qiang and Xi, Chuang and Shen, Chen-Tian and Song, Hong-Jun and Luo, Quan-Yong and Qiu, Zhong-Ling},
  title = {Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells},
  journal = {Endocrine-Related Cancer},
  year = {2023},
  volume = {30},
  number = {9},
  doi = {10.1530/erc-23-0130}
}
Kostenlos starten →